Evaluation of Trazodone in OSA-MCI

Inclusion Criteria: * Able to swallow trazodone capsules * Stable pharmacological treatment of any other chronic conditions for at least 30 days prior to screening * A diagnosis of mild cognitive impairment (MCI) * A diagnosis of obstructive sleep apnea (OSA), and Apnea-Hypopnea Index \> 5 * Neuroimaging obtained during screening consistent with a clinical diagnosis of Alzheimer's disease (AD) and without findings of significant exclusionary abnormalities * Written informed consent to participate in the study provided by the patient Exclusion Criteria: * Diagnosis of dementia, neurodegenerative condition, seizure disorder or other infectious, metabolic, or systemic disease affecting the central nervous system * Vitamin B12 or folate deficiency * Diagnosis of mental health disorders * Nootropic drugs except for AD prescriptions stable for at least 30 days * Suspected or known allergy to trazodone * Intake of drugs or substances potentially involved in clinically significant inhibition or induction of CYP34A or P-gp-medicate drug interactions with trazodone within 4 weeks or 5 half-lives of the interacting drug prior to administration of trazodone and throughout the course of the study * Previous exposure to anti-Aβ vaccines * Concurrent treatment with antipsychotic agents, antiepileptics centrally active antihypertensive drugs, sedatives, opioids, mood stabilizers, or benzodiazepines within 4 weeks of screening visit * Patients who are receiving non-benzodiazepine hypnotics * Clinically significant, advanced, or unstable disease that might interfere with outcome evaluations